Study of Pemetrexed and Bevacizumab in Patients With Head and Neck Cancer

Part of paid clinical trials in Pittsburgh, Pennsylvania.

Sponsor
University of Pittsburgh
Study ID
NCT00222729
Phase
PHASE2
Status
Completed

Conditions

  • Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pemetrexed — DRUG
    500 mg/m2 day 1 q 21 days
  • Bevacizumab — DRUG
    15 mg/kg IV q 21 days following pemetrexed

Study Details

The purpose of this study is to determine if the combination of two new drugs pemetrexed (Alimta) and bevacizumab (Avastin) can increase the effectiveness of treatment for head and neck cancer. Currently pemetrexed is approved by the Food and Drug Administration (FDA) for another type of cancer, mesothelioma, but it is not approved for head and neck cancer.

Key Dates

First listed
Sep 22, 2005
Start date
Nov 30, 2005
Status verified
Jan 2016
Primary completion
Oct 31, 2013
Completion
Oct 31, 2013

Study Design

Enrollment
42 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Pemetrexed & Bevacizumab

Primary Outcome Measure

Time-to-progression (TTP) [ Time Frame: Up to 36 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Hillman Cancer CenterPittsburghPennsylvania15216-

Find similar trials in Pittsburgh, PA

By research site
Hillman Cancer Center· Pittsburgh, PA

Related Studies